Importantly, the co-administration of levobupivacaine effectively suppressed these enhancements, suggesting that levobupivacaine may negatively regulate ACE2-dependent proliferation and metabolic activity in lung adenocarcinoma cells. The gene discussed is ACE2; the disease is lung adenocarcinoma.